NSE
Every company in the roster listed on NSE.
Every company in the roster listed on NSE.
9 of 9 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Alkem LaboratoriesALKEM · NSE | 1 asset: 1 Ph 3 | EvogliptinPhase 3 · Type 2 DiabetesReliable signal | None on record | — | — | — | — |
BioconBIOCON · NSE | 3 assets: 2 approved, 1 Ph 1 | ItolizumabPhase 1 · Psoriasis | None on record | — | $259MMar 2026 | — | $111M |
CiplaCIPLA · NSE | 3 assets: 1 approved, 1 Ph 3, 1 Ph 2 | VildagliptinPhase 3 · Type 2 DiabetesPartial signal | Mar 2027Afrezza · Phase 2 | — | — | — | — |
Glenmark Pharmaceuticals Ltd.GLENMARK · NSE | 3 assets: 3 Ph 3 | AlmonertinibPhase 3 · Non-Small Cell Lung CancerPartial signal | Nov 2026Trastuzumab rezetecan · Phase 1/2 | — | — | — | — |
Lupin LimitedLUPIN · NSE | 3 assets: 2 approved, 1 Ph 3 | BofanglutidePhase 3 · ObesityPartial signal | 30 Jun 2027Bofanglutide · Phase 3 | — | — | Profitable | $233M |
Sun Pharma Advanced Research Company LimitedSPARC · NSE | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Sun Pharmaceutical IndustriesSUNPHARMA · NSE | 6 assets: 4 approved, 1 Ph 3, 1 Ph 2 | LerodalcibepPhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | Apr 2027Utreglutide · Phase 2 | — | $1.0BMar 2026 | Profitable | $401M |
Suven Life SciencesSUVEN · NSE | 2 assets: 1 Ph 3, 1 Ph 2 | MasupirdinePhase 3 · Alzheimer's DiseasePartial signal | Dec 2026Masupirdine · Phase 3 | — | — | — | $33M |
Zydus LifesciencesZYDUSLIFE · NSE | 5 assets: 1 approved, 3 Ph 3, 1 Ph 2 | DesidustatPhase 3 · Chronic Kidney DiseasePartial signal | 31 Dec 2026Saroglitazar · Phase 1 | — | — | — | $256M |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.